CollPlant Biotechnologies (CLGN) Change in Accured Expenses (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly Change in Accured Expenses came in at $22000.0 in Q4 2025, down 31.25% YoY from $32000.0 in Q4 2024, and up 120.37% on a QoQ basis from -$108000.0 in Q3 2025.
CollPlant Biotechnologies (CLGN) Change in Accured Expenses (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of Change in Accured Expenses data on file, last reported at $22000.0 in Q4 2025.
- Quarterly Change in Accured Expenses fell 31.25% year-over-year to $22000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $82000.0 (up 123.23% YoY) and the FY2025 annual result came in at -$46000.0, up 86.97% from the prior year.
- Change in Accured Expenses advanced to $22000.0 in Q4 2025, from -$108000.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $476000.0 in Q4 2022 to a low of -$627000.0 in Q3 2021.
- A 5-year average of -$78157.9 and a median of -$80000.0 in 2021 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2021 — Change in Accured Expenses slumped 433.33% — and 2022, when it surged 202.59%.
- Tracing CLGN's Change in Accured Expenses over 5 years: stood at -$464000.0 in 2021, then surged by 202.59% to $476000.0 in 2022, then plunged by 31.09% to $328000.0 in 2023, then slumped by 90.24% to $32000.0 in 2024, then plunged by 31.25% to $22000.0 in 2025.
- The last three Change in Accured Expenses figures came in at $22000.0 (Q4 2025), -$108000.0 (Q3 2025), and $136000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CollPlant Biotechnologies | 4.26 Mn | 4.26 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22,000.00 |
| Dec 31, 2025 | 22,000.00 |
| Sep 30, 2025 | -108,000.00 |
| Sep 30, 2025 | -108,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Dec 31, 2024 | 32,000.00 |
| Sep 30, 2024 | -52,000.00 |
| Sep 30, 2024 | -52,000.00 |
| Jun 30, 2024 | -394,000.00 |
| Jun 30, 2024 | -394,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Dec 31, 2023 | 328,000.00 |
| Dec 31, 2023 | 328,000.00 |
| Sep 30, 2023 | -102,000.00 |
| Sep 30, 2023 | -102,000.00 |
| Jun 30, 2023 | -88,000.00 |
| Jun 30, 2023 | -88,000.00 |